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Interactions between viruses and the host antibody immune response are critical in the development and control of disease, and
antibodies are also known to interfere with the efficacy of viral vector-based gene delivery. The adeno-associated viruses (AAVs)
being developed as vectors for corrective human gene delivery have shown promise in clinical trials, but preexisting antibodies
are detrimental to successful outcomes. However, the antigenic epitopes on AAV capsids remain poorly characterized. Cryo-
electron microscopy and three-dimensional image reconstruction were used to define the locations of epitopes to which mono-
clonal fragment antibodies (Fabs) against AAV1, AAV2, AAV5, and AAV6 bind. Pseudoatomic modeling showed that, in each
serotype, Fabs bound to a limited number of sites near the protrusions surrounding the 3-fold axes of the T1 icosahedral cap-
sids. For the closely related AAV1 and AAV6, a common Fab exhibited substoichiometric binding, with one Fab bound, on aver-
age, between two of the three protrusions as a consequence of steric crowding. The other AAV Fabs saturated the capsid and
bound to the walls of all 60 protrusions, with the footprint for the AAV5 antibody extending toward the 5-fold axis. The angle of
incidence for each bound Fab on the AAVs varied and resulted in significant differences in how much of each viral capsid surface
was occluded beyond the Fab footprints. The AAV-antibody interactions showed a common set of footprints that overlapped
some known receptor-binding sites and transduction determinants, thus suggesting potential mechanisms for virus neutraliza-
tion by the antibodies.
Antibodies that are elicited against virus capsids represent acritical component of the host protective response in verte-
brates. For most viruses, they control both the susceptibility of an
animal to infection and also the recovery from disease. For human
gene delivery, the presence of preexisting antibodies or antibodies
that develop after administration of viral vectors can create signif-
icant complications for the application or reapplication of thera-
pies (1–4). The host antibody responses initiate through the bind-
ing and activation of B cells and are originally composed of
low-affinity IgM variants; the B cells are subsequently selected for
enrichment of higher-affinity antibody variants, which class-
switch to form IgG1 and other subtypes. However, details of the
production of effective immune responses against viral antigens
and the structural features of epitopes on viruses are still only
partially understood (5–8).
Adeno-associated viruses (AAVs) consist of a T1 icosahedral
capsid composed of three related, overlapping viral structural
proteins (VP1, VP2, and VP3), which differ in their N termini,
while the unique N-terminal region of VP1 (VP1u) is essential for
capsid trafficking within the cell during infection (9–12). VP3 is
contained entirely within the sequence of VP2, which is, in turn,
contained within VP1. In the three-dimensional (3D) structures
of AAVs determined thus far, only the 520 amino acids (aa)
within the VP3 common region have been observed (13–17). VP3
contains an eight-stranded -barrel core, with the -strands
linked by extended loops that form the capsid surface (Fig. 1A).
These loops, the largest of which is the GH loop (230 aa) located
between the G and H strands, also contain stretches of -strand
structure (Fig. 1B). The loops exhibit the highest sequence and
structural variation in the VP3 region and contain nine structur-
ally variable regions (VRs; VR-I to VR-IX) (defined in reference
14) (Fig. 1A and B), which have roles in receptor attachment,
tissue transduction, and antigenicity (reviewed in references 14,
17, 18, 19, and 20). The AAV capsid surface topology (Fig. 1A) is
characterized by prominent features, such as depressions at the
icosahedral 2-fold axis and around a channel-like structure at the
5-fold axis and protrusions that surround each icosahedral 3-fold
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axis. The depressions vary in width, while the protrusions vary in
width and height among different AAVs (14, 15).
Many naturally occurring AAV serotypes and genetic variants
have been identified from humans and nonhuman primates, and
others have been isolated from numerous vertebrates, including
species from the families Equidae, Bovidae, Phasianidae, and Vi-
peridae (21–34). Among the viruses isolated from human and
nonhuman primate tissue, several have been defined as serotypes
because they exhibit little or no antigenic cross-reactivity with sera
specific for other characterized serotypes (AAV1 to AAV5 and
AAV7 to AAV9, with AAV6 being very similar to AAV1) (27, 35).
To date, the genetic variants AAV10 and AAV11 (28), AAV12
(29), and AAV VR-942 (36) have not been serologically character-
ized. In addition to exhibiting antigenic differences, these sero-
types also differ in tissue tropism and receptor binding specificity
and affinity. Each AAV serotype has a distinct ability to transduce
cells and tissues of different hosts when the same transgene is
packaged, indicating that the capsid itself dictates these differences
(27, 37). Many human clinical trials have employed AAV2, the
most studied serotype, but other serotypes and engineered vari-
ants are now being developed in a quest to generate vectors with
improved tissue specificity and transduction efficiency, while also
avoiding the effects of preexisting neutralizing antibodies (see,
e.g., reference 38).
Most people have detectable antibodies against one or more of
the AAV serotypes, with AAV2 being the most prevalent, followed
FIG 1 Variable regions on the AAV capsid surface. (A) Ribbon diagram (left) of an AAV2 VP3 monomer highlights the eight -strands that make up the core
-barrel (gray ribbon) and loops inserted between the strands that make up the capsid surface. The nine AAV variable regions (VR-I to -IX) (defined in reference
14) are colored as follows: I, purple; II, blue; III, yellow; IV, red; V, black; VI, hot pink; VII, cyan; VIII, green; and IX, chocolate. The two -sheets of the -barrel
are indicated by arrows, and the A helix, the DE (between D and E) and HI (between H and I) loops, and N and C termini are labeled. The approximate
positions of the 2-, 3-, and 5-fold axes are indicated by filled oval, triangle, and pentagon symbols, respectively. At right is an AAV2 capsid (gray; assembled from
60 VP3 monomers) showing the location of the VRs, colored as described for panel A, with the HI loop shown in wheat. The approximate positions of the 2-fold
(2F), 3-fold (3F), and 5-fold (5F) axes are indicated by arrows. (B) Superposition of the VP3 monomers for AAV1 (purple), AAV2 (blue), and AAV5 (gray)
showing the variable regions (VR-I to -IX), -sheets, A helix, and the HI loop. The regions with the most notable differences in structure between these viruses,
VR-I, -III, -IV, -V, and -VII, are highlighted (C). AAV6 is structurally identical to AAV1 and is not shown. Inside/outside labels indicate the VP regions at the
interior/exterior capsid surface.
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by AAV1 (39). A small study of 129 people suffering from cystic
fibrosis and 37 unaffected individuals showed that 20 to 30% were
seropositive for AAV6 and that 10 to 20% were seropositive for
AAV5 (40). Low levels of preexisting antibodies were also found
against AAV7 and AAV8, which were originally isolated from
nonhuman primates, whereas little or no human antibody reac-
tivity was detected against rhesus macaque variant AAVrh32.33
(39). Low levels of anti-AAV capsid antibodies can significantly
reduce the effectiveness of gene therapy trials and may also induce
more robust inflammatory responses due to the formation of cap-
sid-antibody immune complexes (4, 41–44). For example, exam-
ination of AAV-specific memory T and B cells in mice showed that
the reduction in virus transduction was primarily caused by AAV-
binding antibodies, which were partially cross-reactive and did
not specifically require AAV-neutralizing antibodies, CD8 T
cells, natural killer (NK) cells, or natural killer T (NKT) cells (45).
The route of delivery of the vector can also affect the breadth of the
antibody responses (46). Approaches taken to avoid the effects of
antibodies include suppression of the immune response with cy-
closporine and other drugs, activation of regulatory CD4 T cells,
and use of alternative virus serotypes as vectors (47–49). Unfor-
tunately, each of these approaches has its disadvantages, a fact
which introduces variability that can complicate already challeng-
ing therapeutic approaches.
Little is known about the antigenic structures of AAV capsids
and how they interact with the antibodies that have been gener-
ated against them. A small number of mouse monoclonal anti-
bodies (MAbs) have been examined that recognize AAV2 capsids
(50) and have been raised against other serotypes (10, 51, 52).
Mutational analysis, peptide insertions and deletions, and linear
epitope mapping methods have been used to characterize the
binding of MAbs to AAV2 (50, 53). Most of these MAbs recognize
conformational epitopes involving capsid structures comprised of
two or more surface loops, with the recognition disrupted when
capsids are disassembled and/or denatured. Recently, the binding
site for a neutralizing antibody against AAV8, ADK8, was charac-
terized by cryo-electron microscopy (cryo-EM) and 3D image re-
construction (cryo-reconstruction) combined with biochemical
and molecular approaches (54). This antibody binds to the pro-
trusions that surround the icosahedral 3-fold axes and affects a
trafficking step post-cell attachment and pre-nuclear entry (54). A
similar structure determination strategy recently confirmed the
binding site of A20, a conformational mouse monoclonal used
extensively in the field, on its target antigen AAV2 (55). This neu-
tralizing MAb bound at a different site on the wall between the
2- and 5-fold axes (plateau) and the floor of the depression sur-
rounding the 5-fold channel (canyon). The neutralizing mecha-
nism for A20 is unknown, but like ADK8 against AAV8, it also
appears to occur at a postentry step.
Here, cryo-reconstruction methods were used to determine
the structures of four different AAV-Fab (fragment antibody)
complexes bound to three different AAV serotypes, AAV1, AAV2,
and AAV5, with one of the AAV1 Fabs also complexed to the
closely related AAV6 capsid. All Fabs bound either on the top or
the side of a 3-fold protrusion, except for AAV5, where the bind-
ing footprint extended from the protrusion toward the 5-fold
channel. The proposed footprints for the Fabs on the different
AAVs mostly overlapped one another and covered receptor bind-
ing sites, such as the heparan sulfate proteoglycan (HSPG) site on
the AAV2 and AAV6 capsids (56–58) and a proposed sialic acid
binding site in AAV5 (59). These results and recently published
cell binding data (52) suggest that virus neutralization by the an-
tibodies investigated occurs via a steric hindrance mechanism,
with the exception of the case of AAV5, which was not neutralized.
MATERIALS AND METHODS
Production and purification of recombinant AAV VLPs. Virus-like par-
ticles (VLPs) of AAV serotypes AAV1, AAV2, AAV5, and AAV6 were
expressed from recombinant baculoviruses that encoded the AAV capsid
open reading frame (ORF). These constructs were produced using a Bac-
to-Bac system (Gibco BRL) as previously described for AAV1, AAV5, and
AAV6 (16, 60, 61). Baculovirus stocks were grown in Sf9 insect cells at
28°C using Sf-900 II SFM medium (Gibco/Invitrogen Corporation). VLPs
were released from the cells by three rapid freeze-thaw cycles in lysis buffer
(50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.2% Triton
X-100), with the addition of Benzonase (Novagen) in the final cycle. The
resulting sample was centrifuged at 10,000  g for 15 min at 4°C to remove
cellular debris. For AAV1, AAV5, and AAV6, the supernatant was diluted
with TNET buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA,
0.2% Triton X-100) and pelleted through a 20% sucrose cushion at
45,000  g for 3 h at 4°C. The pellet was resuspended overnight at 4°C and
then banded on a step gradient (5 to 40% sucrose) at 35,000  g for 3 h at
4°C. VLPs were extracted from the 25% fraction and dialyzed overnight
against phosphate-buffered saline (PBS) with gentle stirring at 4°C. AAV2
VLPs were purified on discontinuous step gradients of iodixanol (5,5=-[(2-
hydroxy-1,3 propanediyl)bis(acetylamino)]bis[N,N=-bis(2,3dihydroxypropyl-
2,4,6-triiodo-1,3-benzenecarboxamide]) (OptiPrep; Nycomed), prepared by
following previously described protocols (62). After centrifugation at
69,000  g for 1 h at 18°C, the 25 to 40% step interface was collected with
a needle and syringe, diluted 2-fold with a low-salt buffer (20 mM Tris-
HCl, pH 8.5, 15 mM NaCl), and loaded onto a heparin-agarose (H6508;
Sigma) column with a 2.5-ml bed volume equilibrated with PBS-MK buf-
fer (1 PBS containing 1 mM MgCl2 and 2.5 mM KCl). The column was
washed with PBS-MK buffer, and the sample was eluted with PBS-MK–1
M NaCl. The eluted fraction was dialyzed against PBS as described above
for the other AAV serotypes. Approximate concentrations for all of the
AAV VLPs were calculated using optical density readings at a wavelength
of 280 nm and an extinction coefficient of 1.7 for concentration in mg/ml.
The VLP concentrations were adjusted to 5 to 10 mg/ml using Centri-
con filters (100,000-molecular-weight cutoff; Amicon), and the purity
and integrity of each VLP sample were monitored using SDS-PAGE and
negative-stain electron microscopy (EM), respectively.
Production and purification of monoclonal antibodies and frag-
ments. The C37-B MAb against AAV2 was produced as previously re-
ported (50). Monoclonal antibodies against AAV1 and AAV5 (Table 1)
were prepared as described by Harbison et al. (52). Hybridomas were
cultured in Dulbecco’s minimal essential medium with 10% fetal bovine
serum and grown in gas-permeable culture bags in 500-ml volumes. In-
tact IgGs (for AAV1, AAV2, and AAV5) were purified using Hi-Trap
Protein G HP columns (GE Healthcare) and eluted from the column with
glycine HCl, at pH 3.0, into collection tubes containing 200 l of 1 M
Tris-HCl, pH 9.0, to ensure a final pH of 7.5 to 8.0. Purified IgGs were
dialyzed overnight into 20 mM sodium phosphate (pH 7.0)–10 mM
EDTA and then concentrated to 20 mg/ml. Samples were then incu-
bated with activated immobilized papain (Pierce) at an enzyme/substrate
ratio of 1:160 (wt/wt) at 37°C for 12 h. The cleaved sample was loaded
on a Hi-Trap Protein A column (GE Healthcare) to remove the Fc regions,
and the Fabs were further purified using gel filtration on a Superdex 75
10/60 column (GE Healthcare).
Sequencing of IgG complementarity-determining regions (CDRs).
The sequences of the heavy- and light-chain variable domains of the
AA5H7.D11 (5H7), AA4E4.G7 (4E4), and BB3C5.3C5 (3C5) IgGs were
determined by reverse transcriptase PCR using various combinations of
mouse IgG-specific primers. Products were cloned into plasmids and se-
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quenced, and the DNA and protein sequences were determined. The
C37-B IgG (50) was not sequenced.
Antibody model building. The IgG variable region sequences for
5H7, 4E4, and 3C5 were submitted to the Web Antibody Modeling
(WAM) server (http://antibody.bath.ac.uk/index.html) to generate 3D
models of their CDRs. This server generates the model piece by piece for
the heavy and light chains and the canonical loops based on the WAM
algorithm (http://antibody.bath.ac.uk/algorithm.html). Briefly, homol-
ogy modeling was used to build the heavy- and light-chain framework of
each antibody structure. The canonical loops were also built through ho-
mology modeling with five rounds of minimization to smooth out joint
regions. The more diverse, noncanonical regions were built using the
combined antibody modeling algorithm (CAMAL) (63).
Preparation of Fab:VLP complexes. VLPs (5.0 to 10.0 mg ml1)
were mixed with Fabs at a ratio of approximately two Fab molecules per
potential binding site on the capsid (molar ratio of 120:1 for Fab:VLP).
Complexes were incubated at 4°C for 1 h and then checked by negative-
stain EM for visual confirmation of successful VLP decoration by Fabs
prior to sample freezing and cryo-EM imaging.
Cryo-EM data collection. Small aliquots (3.5 l) of AAV:Fab com-
plexes were vitrified using standard rapid freeze-plunging procedures (64,
65). Briefly, this involved applying specimen samples to Quantifoil holey
film grids (Quantifoil Micro Tools GmbH, Germany) or homemade grids
with continuous carbon films that had been glow discharged for 15 s in
an Emitech K350 glow-discharge unit, blotting the grids for 5 s with
filter paper, plunging the grids into liquid ethane at 193°C with a man-
ual freezing device, and transferring the frozen grids to liquid nitrogen
and then into an FEI Tecnai Polara sample holder. The samples were
maintained in a vitrified state and imaged in an FEI Tecnai G2 Polara
electron microscope operated at 200 keV, at a nominal magnification of
59,000 and under low-dose conditions (25 electrons/Å2) and with the
objective lens underfocused by 1.25 to 3.0 m. Images were recorded with
a Gatan Ultrascan 4000 charge-coupled-device (CCD) camera at a nom-
inal step size of 1.883 Å/pixel, saved in Gatan DM3 format, and later
converted to a tiff format for processing.
Three-dimensional image reconstructions of AAV:Fab complexes.
Individual particle images were extracted from the micrographs and pre-
processed, and their defocus values were estimated using the RobEM pro-
gram (http://cryoEM.ucsd.edu/programs.shtm) (66). The AUTO3DEM
program (67) was used as previously described (68) to generate an initial,
low-resolution (30 Å) 3D reconstruction of each complex from a set of
150 particle images using the random-model computation procedure
(69). This reconstruction was used to initiate full orientation and origin
determination as well as refinement of the entire set of images for each
complex using the latest version of AUTO3DEM (67). Corrections to
compensate for the effects of phase reversals caused by the microscope
contrast-transfer function were performed as previously described (70,
71), but amplitude corrections were not applied. Final 3D maps, recon-
structed from the selected particle images, were estimated to be reliable to
between 11- and 23-Å resolution (Table 1), based on a conservative Fou-
rier shell correlation threshold of 0.5 (72). The absolute handedness of
each reconstructed density map was adjusted if necessary based on knowl-
edge of several AAV crystal structures (13, 16; also unpublished data)
(Research Collaboratory for Structural Bioinformatics [RCSB] Protein
Data Bank [PDB] numbers 3NG9 and 3NTT for AAV1 and AAV5, respec-
tively). Graphical representations of the reconstructed maps were gener-
ated with the RobEM (http://cryoEM.ucsd.edu/programs.shtml) and
Chimera (http://www.cgl.ucsf.edu/CHIMERA) visualization software
packages (66, 73).
Fitting of atomic and pseudoatomic models into cryo-EM density
maps. The coordinates of the 60-mer all-atom VP3 molecules (for each
capsid) taken from the crystal structures of AAV1 (PDB accession number
3NG9), AAV2 (PDB accession number 1LP3) (13), AAV5 (PDB accession
number 3NTT), and AAV6 (PDB accession number 30AH) (16) were
extracted and docked as rigid bodies into the corresponding density maps
of the AAV:Fab complexes using the COLORES program in the SITUS
software package, version 2.3 (74). Following visual inspection of the
docked models in the program COOT (75), the absolute scale of each map
was determined by generating a series of AAV:Fab cryo-reconstructions at
various sizes using the program Uniconv (http://cryoEM.ucsd.edu
/programs.shtm) and comparing these to an electron density map that
was computed from structure factors calculated for each docked homol-
ogy model (“model map”) at cell dimensions and grid sizes matching each
of the scaled maps. The respective cryo-reconstructions and model maps
were then normalized by means of the program MAPMAN (http://xray
.bmc.uu.se/usf/mapman_man.html) (76) and compared using the pro-
gram’s similarity function. The highest correlation coefficients for the
maps were obtained for pixel sizes ranging from 1.800 to 1.883 Å (the
original scale), and these values were then used to compute each AAV:Fab
density map at the correct size.
Difference maps were generated in MAPMAN using the operation
function (OP), which subtracted a model map from the corresponding,
scaled AAV:Fab cryo-EM density map. Positive difference density, repre-
senting portions of structure not accounted for by the capsid atomic
model, was interpreted as the bound Fab. Initial pseudoatomic modeling
of the Fab densities used the coordinates of three generic Fab structures
(PDB 2FBJ (IgA) (77), 8FAB (IgG1) (78), and 1ETZ (IgG2B) (79) to assess
different elbow angles and variable region structures and, in particular,
the complementarity-determining region 3 (CDR3). For AAV2:C37B (for
which there was no WAM model), density corresponding to a single Fab
was extracted from the reconstruction using the voledit program in SITUS
(74), and the 2FBJ Fab coordinates were manually fit within the density,
followed by refinement with the “fit-in-map” function in Chimera (80).
The fit with the highest correlation coefficient was accepted as the final fit.
The PDBs for the 8FAB and 1ETZ Fabs were then aligned with the docked
2FBJ Fab to assess the effects of the elbow angles and CDR structures on
the overall fit and analysis. The 5H7 and 4E4 Fabs against AAV1 had
overlap between the footprints of their bound Fabs and were thus docked
differently. The 2FBJ Fab coordinates were manually docked into the pos-
itive density for one Fab in each difference map using Chimera (74), and
a “full” capsid pseudoatomic model of each AAV:Fab complex was gen-
erated by applying icosahedral (5-3-2 point group) symmetry to the VP3:
Fab heterodimer model. Structure factors were calculated from the VLP:
Fab pseudoatomic model coordinates using the bsf function in the Bsoft
program (81), taking partial occupancy into account where relevant, and
electron density maps were generated. The fit-in-map function in Chi-
mera was used to compare each AAV:Fab cryo-reconstruction to the cor-
responding map of the AAV:Fab model for quantitative assessment of the
Fab docking. The WAM models for the sequenced CDRs of 5H7 and 4E4
were then superimposed onto the corresponding docked portion of the
















AAV1:4E4 95 1.5–3.0 2,376 (1,914) 12 0.89,* 0.77‡
AAV1:5H7 31 1.25–3.0 313 (262) 23 0.89,† 0.69‡
AAV2:C37-B 149 1.5–3.0 4,731 (4,392) 11 0.82‡
AAV5:3C5 122 1.25–3.0 2,806 (2,552) 16 0.87‡
AAV6:5H7 49 1.0–3.0 5,265 (2,527) 15 0.89,† 0.69‡
a Recorded with a CCD camera (4,000 by 4,000 pixels).
b Range of objective lens defocus settings.
c Values in parentheses are the number of particles used in reconstruction.
d Estimate of resolution limit, rounded to nearest Å unit, based on a Fourier shell
correlation threshold of 0.5 (72).
e Correlation coefficient values for all atom models for Fab and capsid, which reflect the
agreement between the model and experimental density maps at the specified
resolution. Values were calculated during the map-in-map fitting program provided in
Chimera (73). *, calculated with an occupancy of 0.5; †, calculated with an occupancy
of 0.3; ‡, calculated with an occupancy of 1.
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2FBJ structure with the secondary structure matching (SSM) superimpose
operation in COOT (82). This enabled the identification of the regions of
each AAV capsid surface that interacts with the Fab loop regions. All
visualization and analysis of these models were performed with Chimera
(73) and PyMOL (version 1.3r1; Shrodinger, LLC, New York, NY). A
similar strategy was used for fitting 5H7 bound to AAV6. Fitting for the
3C5 Fab (bound to AAV5) density involved using a similar IgG isotype,
IgG3 (PDB 3IJH) (83), and manually docking the four regions (heavy and
light chains and variable and constant regions) into the Fab density. The
correlation coefficient between the reconstructed density and fitted com-
plex model was calculated as described above for the AAV1:Fab com-
plexes. Two sites were chosen as the potential Fab contact sites based on
proximity of high sigma threshold density to the capsid surface. All
docked Fabs and AAV monomers were analyzed with the programs
COOT (75) and PDBePISA (84) to further assess the interfaces in the
proposed epitopes. Interacting VP and Fab residues were defined as being
within 4.0 Å in PDBePISA (84).
RESULTS
The structures of five different AAV VLP:Fab complexes were ex-
amined by means of cryo-reconstruction methods at estimated
resolution limits ranging from 11 to 23 Å (Tables 1 and 2; Fig. 2).
The 5H7 Fab was complexed with AAV1 and AAV6 since it cross-
reacts with both viruses. With the exception of the 3C5 antibody
against AAV5, all other antibodies used in this study have been
shown to be neutralizing (50, 52). For each complex, the final
reconstructed density map was initially scaled to the coordinates
of the corresponding AAV capsid crystal structure to determine an
absolute map scale (pixel size) prior to the calculation of differ-
ence density maps for interpretation and pseudoatomic model
building for the bound Fabs (see Materials and Methods). This
conservative protocol avoids potential pitfalls of overfitting and
does not alter the target map or the input coordinates to allow for
conformational differences between the two components. The
correlation coefficients computed when cryo-reconstructed and
model maps were compared, based on site occupancy, ranged
from 0.82 to 0.89 (Table 1). These values support the validity of
the models generated for the complexes: variation likely arises
from the use of generic Fab structures and sequences and because
actual elbow angles are not known. The binding sites (footprints
or epitopes) for the four different Fabs on the five AAV capsid
surfaces were analyzed to define the contact between AAV VP3
residues and the CDRs of the Fab models. The surface areas oc-
cluded by the Fabs on the AAV capsids (Table 2) were within the
range previously reported for antigen-antibody complexes, in-
cluding that for canine parvovirus (CPV) bound with Fabs from
several neutralizing MAbs (1, 85–87).
Antibody binding to AAV1 and AAV6. The two different an-
tibodies against AAV1, 4E4 and 5H7 (Table 1), both bound to the
protrusions surrounding the 3-fold axis of the capsid but on dif-
ferent surfaces. Fab 4E4 bound to the outer side of the protrusion
(i.e., facing away from the 3-fold axis), with the long axis of the Fab
pointing toward and across the icosahedral 2-fold axis, while por-
tions of the variable region of the Fab overlap the variable region
of a 2-fold-related Fab (Fig. 2A and 3A to D). Consistent with this
interpretation, density attributed to the Fab constant and variable
chains was approximately 50% of the magnitude (1.0-	 thresh-
old) of the density observed for the virus capsid and variable re-
gion (2.3-	 threshold). Thus, steric hindrance permits only one of
two overlapping Fabs to contact the AAV1 capsid at a time (Fig.
3C and D). Residues that comprise the proposed conformational
footprint of the fitted 4E4 Fab include 456-AQNK-459 (AAV1
numbering) from one VP monomer and residues 492-TKTDNN
N-498 from a 3-fold-related VP monomer (Table 2). These resi-
dues correspond to VR-IV and VR-V (Fig. 1), respectively (de-
fined in reference 14). Based on a fitted Web Antibody Modeling
(WAM) model of the 4E4 Fab, the PDBePISA application (84)
also identified potential interactions at 458-NK-459 on one VP
monomer and at 493-KT-494 from the symmetry-related mono-
mer. Although a structure was not determined for 4E4 bound to
the AAV6 capsid surface in this study, based on the sequence con-
servation of these regions to AAV1, it is predicted that the same
site would be recognized on the AAV6 capsid surface. Of note,
TABLE 2 Epitopes proposed for the AAV:Fab complexes and their footprint areas
AAV:Fab complex
Proposed epitope
Surface area (Å2)cName Descriptiona
AAV1:4E4 VR-IV 456-AQNK-459 1,197
VR-V 492-TKTDNNN-498 (3-fold)b
AAV1(AAV6):5H7d VR-V T494  496-NNNS-499 1,360
VR-VIII 582-VN-583  588-STDPATGD-595  H597
AAV2:C37-B VR-V 492-SADNNNS-498 1,230
VR-VIII 585-RGNRQ-589 (3-fold)b
AAV5:3C5
Site A VR-I 254-SVDGSNAN-261 1,728
VR-III 374-DN-375
VR-V R483, 485-SVSAFATT-492, R494, E496, 499-GAS-501
Site B VR-I Q246 1,137
VR-VII N530, 532-QPANPGT-538
HI loop S651, 653-VP-654, 656-SS-657 (5-fold)b
VR-IX 704-DSTGE-708
a Residue numbering corresponds to that for each of the individual serotypes.
b Symmetry relation of residues to the reference VP monomer.
c Surface area calculation taken from PDBePISA (84) and rounded to the nearest Å2.
d AAV1(AAV6), 5H7 cross-reacts with AAVI and AAV6. Capsid residues 582-VN-583 and H597 near VR-VIII and T494 near VR-V flank () the indicated sites but do not interact
directly with the CDRs in the docked Fab models.
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residue K459 is reported to be important for heparan sulfate pro-
teoglycan (HSPG) recognition by AAV6 (88).
The 5H7 antibody, which cross-reacts with AAV1 and AAV6
(as does 4E4), binds to equivalent regions in the capsids of these
two viruses. The 5H7 footprint occurs at the “inward-facing side”
of the protrusions surrounding the icosahedral 3-fold axis, and the
density was centered at the axis (Fig. 2B and C and 4A). The den-
sity in this part of the cryo-reconstruction is consistent with only
one Fab, on average, binding to a group of three protrusions. The
averaged density for the Fab CDR in contact with the protrusions
was observed at a threshold (2.2 	) similar to that for density in the
capsid, whereas the constant regions of the Fabs were observed
only at approximately one-third of that density (0.6 	). The
CDRs in the docked Fab model span two protrusions (Fig. 4B). In
this mode of binding, one Fab molecule is bound such that two
3-fold-related sites are sterically blocked, and there is no overlap
of the constant regions, which have occupancy of 0.3. The 5H7
footprint mapped to two adjacent AAV1 VP monomers, as ob-
served for the 4E4 binding, but with VR-VIII and VR-V predicted
as the sites of interaction (Fig. 4B). Unlike the case in 4E4, two
VR-VIIIs from two adjacent VP monomers contribute to the 5H7
epitope. Using the WAM-generated Fab model fitted into the den-
sity, the PDBePISA application (84) identified residues 496-
NNNS-499 in VR-V and 588-STDPATGD-595 in VR-VIII in one
VP (Table 2) as contributing the 5H7 epitope. Capsid residues,
582-VN-583 and H597 near VR-VIII and T494 near VR-V, flank
these sites but do not interact directly with the CDRs, based on
distance measure cutoffs, and thus may be involved in stabiliza-
tion of the Fab at the capsid surface.
Antibody binding to AAV2. The C37-B MAb is specific for
AAV2 and does not cross-react with other serotypes tested (50).
Density for the Fab was observed at the top of each of three pro-
trusions surrounding the 3-fold axis, extending in a radial direc-
tion away from the capsid surface; all 60 sites on the capsid were
occupied (Fig. 2D). With no sequence available for C37-B, the
atomic model of an unrelated Fab (PDB 2FBJ) (77) was docked
into the AAV2:C37-B density map to assign the C37-B footprint
on AAV2. The binding footprint was located at the top of the
protrusions (Fig. 5A) and includes VR-V and VR-VIII (Fig. 5B), as
was found for the 5H7 footprint on AAV1 (Table 2). The VR-V
contact overlapped the 4E4 footprint on AAV1 (Table 2). How-
ever, the 4E4, 5H7, and C37-B Fabs have distinct orientations with
respect to the capsid surfaces (compare Fig. 2A and B with D). The
C37-B footprint included 492-SADNNNS-498 (AAV2 VP1 num-
bering) in VR-V from one VP monomer and 585-RGNRQ-589 in
VR-VIII from the 3-fold symmetry-related VP (Table 2) by con-
tact analysis in the COOT program (75). Both regions were also
identified by the PDBePISA (84) although VR-V was narrowed to
the ADNN four-residue stretch by this application. The VR-V
residues correlate with previous peptide mapping results where a
peptide scanning approach was used to identify two AAV2
stretches (aa 492 to 503 and 601 to 610) as the binding site for
C37-B (50). The first of these peptides lies at the surface of the
3-fold protrusion in VR-V, and the second is buried just below the
depression at the 3-fold axis. Significantly, residues 492 to 498 lie
within the previously mapped epitope and are centrally located
within the first peptide sequence, which includes N495 and N496.
Mutation of these residues caused a partial reversal of C37-B MAb
competition (50). The peptide scanning experiments did not,
however, identify the VR-VIII interactions observed in this study.
FIG 2 Cryo-EM reconstructions for the AAV:Fab complexes. (A) AAV1:4E4
complex at 12 Å. (B) AAV1:5H7 complex at 23 Å. (C) AAV6:5H7 complex
at 15 Å. (D) AAV2:C37B complex at 11 Å. (E) AAV5:3C5 complex at 15
Å. The isodensity for each virus-Fab complex is shown (left column) with the
antigenic epitopes depicted on a roadmap (103) (right column). Viral surfaces
are colored as follows: AAV1, purple; AAV6, pink; AAV2, blue; and AAV5,
gray. Fab density is rendered in light grayscale in all cryo-reconstructions ex-
cept for AAV5, in which the Fab density is dark gray. The arrows on the
AAV1:4E4 complex point to approximate locations of the icosahedral symme-
try 3- and 5-fold axes indicated by 3F and 5F, respectively. In each roadmap,
the Fab footprint is indicated by the capsid color. All density maps are viewed
down a 2-fold axis, as indicated by the oval in the accompanying roadmap
images. The large open, black triangle on each roadmap depicts a viral asym-
metric unit bounded by one 5-fold axis (filled pentagon), two 3-fold axes
(filled triangles), and one 2-fold axis (filled oval). In the roadmap of panel E,
the dark and light gray footprints represent the contacts between the AAV5
capsid and the constant and variable regions of the 3C5 Fab, respectively.
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Notably, the region identified within VR-VIII contains two critical
arginines, R585 and R588, both of which are important in AAV2
binding to the HSPG receptor (Fig. 5B) (56, 57), and this is con-
sistent with the reported receptor-blocking ability of the C37-B
antibody (50).
Antibody binding to AAV5. The 3C5 Fab bound to all 60 sites
on the AAV5 capsid but adopted a tangential orientation that
obscures a large fraction of the capsid surface, except at the 3-fold
axis (Fig. 2E). The density seen in the AAV5:3C5 map thus sug-
gested that both the variable and constant regions of the Fab con-
tact the capsid surface. A difference map generated by subtracting
a map of the capsid model from that of the virus-Fab cryo-recon-
struction and contoured at a high density threshold (4.0 	)
aided in the assignment of the potential Fab interaction sites. Two
regions of high density were observed: (i) the raised capsid region
between the 2-fold and 5-fold depression (2-/5-fold wall) (Fig. 6A,
solid box) (site A) and (ii) the region extending from the 2-/5-fold
wall toward the 5-fold axis of symmetry (Fig. 6A, dashed box) (site
B). Fitting of a Fab model into positive difference density used
variable and constant domains that were separated but held in
register. During this analysis it was evident that the constant do-
main of the Fab fitted best into the density designated site A while
the wider, variable portion of the Fab structure appeared to fit
better into the density at site B. These two sites encompass multi-
ple VRs: site A includes residues 254-SVDGSNAN-261 in VR-I,
374-DN-376 in VR-III, and R483, 485-SVSAFATT-492, R494,
E496, and 499-GAS-501 in VR-V; site B includes residues N530
and 532-QPANPGT-538 in VR-VII, 704-DSTGE-708 in VR-IX,
and Q246 near S651, 653-VP-54, and 656-SS-657 in the HI loop
located between the H and I strands (Table 2 and Fig. 6B and
C). AAV1 capsids were shown to cross-react with the 3C5 mono-
clonal antibody (52), and a structural alignment of AAV5 and
AAV1 identified both sequence and structural conservation of res-
idues S254, 258-SN-259, and N261 in AAV5 (highlighted in yel-
FIG 3 Pseudoatomic model for the AAV1:4E4 Fab complex. (A) A single fitted Fab model (purple ribbon) is shown in the cryo-reconstructed density (gray mesh
contoured at 0.5-	 threshold) with the complementarity-determining region (CDR) in close proximity to one 3-fold protrusion (black oval). This view
emphasizes the additional density across the 2-fold axis corresponding to the location of the 2-fold-related Fab. The rectangular box delineates the approximate
position of the icosahedral 2-fold axis (showing two adjacent helices and protruding VR-IX loops) for the views shown in panels B and D. (B) The figure is the
same as that in panel A rotated by 90° about the y axis to view the structure from one 3-fold protrusion to another across the 2-fold axes. (C) The figure is the same
as that in panel A but with a second Fab model (salmon ribbon) built into the reconstructed density map. This view highlights the overlap between portions of
the variable regions of the Fabs bound to each site on the sides of each 3-fold protrusion. (D) The figure is the same as that in panel C rotated 90° about the y axis
to show the accommodation of the second Fab structure in the reconstructed density map. The approximate location of the VRs for the 3-fold protrusions are
labeled in panels A and B as follows: , VR-IV (gray); ε, VR-V (hot pink); ¤, VR-VIII (gray).
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low in Fig. 6B and C) with S264, 268-SN-269, and N271 in AAV1
(data not shown) within the footprint. This suggests that the
AAV1 interaction may be mediated by the constant region of the
Fab. While verification of site B as the CDR binding epitope is
required, it is interesting that these residues are located in capsid
locations similar to the epitope footprint mapped for the A20
antibody against AAV2 (50, 55, 89). Of all the Fab footprints iden-
tified in this study, 3C5 was the least well defined and would ben-
efit from further cryo-EM studies with either the F(ab=)2, the in-
tact IgG, or the Fab linked to gold, as well as from mutational
analysis of the predicted epitope region for a better understanding
of its nonneutralization phenotype.
DISCUSSION
In this study, we have defined the epitope structures on the capsids
of AAV1/AAV6 (AAV1/6), AAV2, and AAV5 that are recognized
by a set of mouse monoclonal antibodies. The 4E4 and 5H7 anti-
bodies, both of which recognize intact AAV1 and AAV6 capsids,
were produced after extended immunization of mice, as was the
C37-B IgG against AAV2, and likely represent affinity-mature
IgGs. The 3C5 antibody elicited against AAV5 was generated only
4 days after AAV5 capsid immunization of a mouse that had been
previously immunized with AAV1. Therefore, 3C5 may represent
an affinity-immature antibody (52). Furthermore, it is interesting
that the A20 monoclonal, also an IgG3 (50), is reported to interact
with similar regions on the AAV2 capsid (55), which is one of the
most divergent serotypes from AAV5 (27).
The binding sites for the AAV1/6 and AAV2 antibodies on the
different AAV serotypes showed significant overlap with the
epitopes mapping close to or on the protrusions that surround
the 3-fold axes (Fig. 2A to D). However, the specific sites of inter-
action varied, with some antibodies binding closer to the top and
FIG 4 Pseudoatomic model of the AAV1:5H7 Fab complex. (A) Stereo view of three Fab models (red, cyan, and yellow) fitted into density (gray mesh, contoured
at a 0.5-	 threshold) protruding from the depression (center) at the icosahedral 3-fold axis. The three VP3 monomers that surround the 3-fold axis are also
depicted in red, cyan, and yellow. (B) Enlarged side view of the figure shown in panel A showing a single Fab model (gray). The Fab footprint includes VR-V and
VR-VIII (red sticks) of one VP monomer.
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others on the side of these morphological features. Although the
basis of antigenic variability among different AAV serotypes has
yet to be fully defined, the high amino acid sequence variation in
the AAV VP loops that form the 3-fold protrusions and the local-
ization of the Fab footprints to these structures indicate that these
regions influence AAV serological differences. All footprints oc-
cluded adjacent capsid VP subunits, indicating that the virus sur-
faces form conformational rather than linear epitopes. This is con-
sistent with no reactivity with denatured capsids, as determined by
dot blot analyses for the 4E4, 5H7, and 3C5 antibodies (data not
shown), and previous reports that the AAV2 C37-B antibody rec-
ognizes intact capsids (50). A structural superposition and struc-
ture-based sequence alignment of AAV1, AAV2, and AAV6 (Fig.
1B and 7) show that the amino acids of each epitope include vari-
able stretches of sequences that adopt different surface loop con-
formations (Fig. 1C) (14, 16). Despite this high variability, the
epitopes form similar structural features, such as the protrusions
surrounding the 3-fold axis or the raised region of the capsid be-
tween the 2- and 5-fold axes. Significantly, the ADK8 epitope that
mapped onto the AAV8 capsid surface involved VR-VIII (54).
Thus, the common AAV VRs appear to confer serotype specificity,
suggesting roles in antigenic diversity between the AAVs.
The surfaces of the AAV capsids contacted by the Fabs, includ-
ing those known to neutralize AAV1 (e.g., 4E4 and 5H7) (52) and
AAV2 (e.g., C37-B) (50), did not exhibit any obvious characteris-
tic features other than being at or adjacent to a raised protrusion
on the capsid surface. Recognition of these morphological features
by antibodies is not surprising since these are the most highly
FIG 5 Pseudoatomic model of the AAV2:C37-B Fab complex. (A) Stereo view of a trimer of 3-fold-related VP3 monomers (red, black, and cyan) with a trimer
of identically colored Fab models shown within the cryo-reconstructed density (gray mesh contoured at a 0.5-	 threshold). (B) Enlarged side view of the figure
shown in panel A of one fitted Fab model (red) that lies above a 3-fold protrusion (in gray ribbon). The epitope consists of VR-V (cyan, 493-ADNNN-496) and
VR-VIII (purple, 585-RGNRQ-589). The arginine residues (585 and 588) in VR-VIII that are involved in HSPG binding of AAV2 are rendered as sticks (C
terminus in magenta; N terminus in blue). This epitope mapping is consistent with C37-B neutralization of AAV2 steric hindrance of cell surface receptor
binding.
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exposed portions of the capsid surface. This is a common feature
for antigenic sites on other parvoviruses, such as AAV8, CPV, and
feline panleukopenia virus (FPV), as well as other viral capsids
(1, 85–87). However, being raised and/or exposed does not guar-
antee that a particular feature will serve as an antigenic determi-
nant. For example, the cylinder-shaped surface feature that sur-
rounds each 5-fold axis of symmetry in the AAV capsids did not
bind antibodies, and the same features in CPV and FPV capsids
also did not bind any of the eight antibodies that have been exam-
ined (86). This suggests that structural prominence alone is not
sufficient to induce antibody recognition.
The binding orientations observed for most of the Fabs used in
this study, coupled with the known flexibility of IgG (90) struc-
tures, indicate that most of the MAbs could not bind bivalently to
a capsid. Overall, the different AAV footprints are hydrophilic and
include a predominance of polar amino acids, but the residue
compositions do not differ significantly from those in the remain-
ing portions of the capsid surfaces. Some of the residue types in the
epitopes were repeated, with instances of identical three-residue
stretches (Table 2 and Fig. 7). The significance, if any, of this
observation is unknown.
Numerous studies of other viruses have demonstrated that an-
tibody neutralization can occur by any one of several different
mechanisms. These include the following: (i) competition for re-
ceptor attachment sites, (ii) abrogation of postentry events during
endosomal trafficking, and (iii) stabilization of the capsid against
structural changes required for uncoating within the cell (8, 87,
91). Antibodies may block cellular attachment by binding directly
to the receptor binding site, or they may block attachment by
occluding other regions on the capsid surface when they attach to
the capsid in a more tangential orientation. The neutralization
mechanisms used by anti-AAV antibodies have yet to be fully
investigated although some information is available for some of
the antibodies used in this study. The capsids of different AAV
serotypes bind a variety of cellular receptors, including glycans
such as HSPG, sialic acid, and galactose, and glycoproteins such as
51 integrin and platelet-derived growth factor receptor (35,
92–97). For AAV2, the HSPG binding site is close to or overlaps
the residues that were identified by peptide mapping to bind the
C37-B antibody. C37-B reduces attachment to HSPG (50, 98),
which is consistent with the AAV2:C37-B structure (Fig. 2D)
where the antibody footprint overlaps the HSPG receptor binding
site (Fig. 5B) (56, 57, 99, 100). Monoclonal antibodies 5H7 and
4E4 neutralize cellular infection by AAV1, whereas 3C5 directed
against AAV5 had only minor effects at very high antibody con-
centration (52). The 5H7 and 4E4 antibodies both inhibited cell
surface association, suggesting competition with a cell surface re-
ceptor, and 4E4 also neutralized virus attachment and entry at
high concentrations (52). One of the proposed 5H7 contact pep-
tides, 588-STDPATGD-595, maps structurally close to the posi-
tions of two (aa 584 and 598) of the six residues that distinguish
the AAV1 and AAV6 capsid VP subunits and, along with residue
531, are reported to influence tissue transduction differences be-
tween these two AAV serotypes (16, 58, 101, 102). In addition, one
of the proposed 4E4 contact peptides, 456-AQNK-459, includes
K459, which is involved in HSPG binding by AAV6 (88). Further-
more, 4E4 binding across the 2-fold axes occludes access to E531/
K531 in AAV1/AAV6, respectively, and K531 is known to be in-
volved in HSPG binding by AAV6 (58). These observations
support a study that suggests that the neutralization mechanisms
FIG 6 Pseudoatomic model of the AAV5:3C5 complex. (A) Positive differ-
ence density (at a threshold of 4 	) is shown as the black mesh on the light
gray AAV5 capsid model surface. The black oval depicts the region covered by
one entire Fab molecule, with the two regions of high-density threshold delin-
eated by solid and dashed boxes. The first region (solid box, site A) is on the
2-/5-fold wall and the second region (dashed box, site B) extends from the
2-/5-fold wall toward the 5-fold axis. (B) Surface representations of three
AAV5 VP3 monomers (in shades of gray) highlighting capsid regions involved
in contact with the 3C5 Fab. Site A (red) includes four residues common to
AAV1 (in yellow), while site B (blue) is shared between two adjacent, 5-fold
symmetry-related monomers and includes residues in the HI-loop located on
the floor of the 5-fold depression. (C) Stereo image of the Fab density and fitted
structures. The two 5-fold-related monomers are shown as gray ribbons, and
the proposed epitopes are thickened and colored as mentioned above (site A,
red; site B, blue). The yellow region represents identical residues found in the
AAV1 capsid. The Fab models were fit into the reconstructed density map at a
threshold of 0.5 	. Variable, cyan; constant, purple.
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of these two antibodies involve occlusion of the receptor binding
sites (52). Also, 4E4 may inhibit a step that occurs after receptor
attachment. The lack of robust neutralization of AAV5 by the 3C5
Fab is consistent with that antibody making contact but leaving
the 3-fold axes exposed and thus potentially accessible to recep-
tors. Furthermore, residue A581 is proposed to play a role in sialic
acid recognition and airway cellular transduction in AAV5 (59)
but is not part of the Fab binding footprint, which is consistent
with lack of virus neutralization by the antibody.
Here, we have shown that several mouse monoclonal antibod-
ies raised against AAV capsids recognize a relatively small portion
of the protrusions that surround each 3-fold axis, but there is
variability in the mode and stoichiometry of binding. If human
antibodies bind similarly to small regions of the AAV capsids, it
should be possible to engineer mutations in AAV capsids that
block a variety of antibody interactions, e.g., by introduction of
insertion peptides at the mapped sites or by introduction of non-
conserved and nonrepeated amino acid sequences. It would also
be of interest to determine if different isotypes or subclasses of
antibodies prefer certain regions or structures on the capsid sur-
face. Such changes could preclude the binding of most antibodies
while retaining functions needed to deliver genetic payloads to
target tissues.
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